Voltage-dependent calcium channel subunits (CACNA2D2, CACNA2D3, and CACNA1G) (CACNA2D2/CACNA2D3/CACNA1G)

This target entry represents a grouping of three distinct voltage-dependent calcium channel subunits: the auxiliary alpha-2/delta subunits CACNA2D2 and CACNA2D3, and the pore-forming T-type alpha-1 subunit CACNA1G. CACNA2D2 and CACNA2D3 are critical for the trafficking, membrane expression, and biophysical modulation of high-voltage-activated calcium channels, thereby influencing neurotransmitter release and neuronal excitability (UniProt O60218, Q8IZS8). CACNA1G (Cav3.1) is a low-voltage-activated channel that mediates T-type calcium currents, which are essential for rhythmic burst firing and pacemaker activity in the central nervous system and heart (UniProt O43497). These subunits are implicated in a variety of neurological disorders, including childhood absence epilepsy and neuropathic pain, as well as in oncogenesis where CACNA2D2 and CACNA2D3 often function as tumor suppressors (PubMed: 22403570). Pharmacologically, CACNA2D2 is a target for gabapentinoids like gabapentin and pregabalin, which bind the alpha-2/delta subunit to modulate synaptic transmission. CACNA1G is primarily targeted by T-type calcium channel blockers such as ethosuximide and zonisamide to manage seizure activity (PubMed: 17112624). Because these subunits represent distinct genetic entities with different physiological roles, they are typically categorized as separate therapeutic targets in drug development.

Other names

Alpha-2/delta-2 calcium channel subunitAlpha-2/delta-3 calcium channel subunitCav3.1T-type calcium channel alpha-1G subunitVoltage-dependent calcium channel subunit alpha-2/delta-2Voltage-dependent calcium channel subunit alpha-2/delta-3Voltage-dependent T-type calcium channel subunit alpha-1G

Inhibition of calcium channel trafficking and modulation of channel kinetics via alpha-2/delta subunit binding, and direct pore blockade of low-voltage-activated T-type calcium channels.